BioCardia initiates patient enrollment at Emory University for Phase III heart failure trial

BioCardia, Inc.

Emory University School of Medicine is now enrolling patients with ischemic heart failure in BioCardia's pivotal Phase III CardiAMP HF II trial.
Dr. Arshed Quyyumi, Professor of Medicine at Emory, will serve as principal investigator for the autologous cell therapy study.
Trial compares CardiAMP therapy to placebo; target enrollment completion in 2027 based on prior positive results presented at ACC 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.